Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

MPO as a Novel Susceptibility Gene in Myeloid Malignancies

Samuel Li, BA, Ruipeng Wei, Janet Wang, Undergraduate, Vera Adema, PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Yasunobu Nagata, MD PhD, Cassandra M Kerr, MS, Babal K. Jha, PhD, Francesc Sole, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Thomas Laframboise, PhD

Blood (2019) 134 (Supplement_1): 5402.

https://doi.org/10.1182/blood-2019-122127

Published: 2019

Journal Articles

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

Blood (2019) 134 (Supplement_1): 1200.

https://doi.org/10.1182/blood-2019-132005

Published: 2019

Journal Articles

ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia

Teodora Kuzmanovic, Bhumika J. Patel, MD, Jibran Durrani, Hassan Awada, MD, Cassandra M Kerr, MS, Bartlomiej P. Przychodzen, Samuel Li, BA, Seth J. Corey, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Thomas Laframboise, PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4233.

https://doi.org/10.1182/blood-2019-130520

Published: 2019

Journal Articles

LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes

Courtney Hershberger, BS, James Hiznay, Rosemary Dietrich, Xiaorong Gu, PhD, Cassandra M. Hirsch, Amy Graham, BS, MS, Bartlomiej P. Przychodzen, Valeria Visconte, PhD, Vera Adema, PhD, Yvonne Parker, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, Richard A Padgett

Blood (2018) 132 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2018-99-112838

Published: 2018

Journal Articles

Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS

Cassandra M. Hirsch, Wenyi Shen, MD, Bartlomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, PhD, Teodora Kuzmanovic, BA, Louis Williams, MD MBA, Aziz Nazha, Valeria Visconte, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2018-99-116535

Published: 2018

Journal Articles

Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

Aziz Nazha, Manja Meggendorfer, PhD, Sudipto Mukherjee, MD PhD MPH, Wencke Walter, PhD, Stephan Hutter, PhD, Ahed Makhoul, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Hetty E. Carraway, MD MBA, Yasunobu Nagata, Yihong Guan, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, Jaroslaw P. Maciejewski, Claudia Haferlach, MD, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD

Blood (2018) 132 (Supplement 1): 2809.

https://doi.org/10.1182/blood-2018-99-114782

Published: 2018

Journal Articles

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Teodora Kuzmanovic, Bhumika J. Patel, MD, Srinivasa Reddy Sanikommu, MD, Yasunobu Nagata, Hassan Awada, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Remco J Molenaar, MD PhD, Babal K. Jha, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, Tomas Radivoyevitch, PhD

Blood (2018) 132 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2018-99-119950

Published: 2018

Journal Articles

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

Blood (2018) 132 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2018-99-116685

Published: 2018

Journal Articles

Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes

Blood (2018) 132 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2018-99-115154

Published: 2018

Journal Articles

Distinct Features of Chip-Derived and De Novo MDS

Blood (2018) 132 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2018-99-117763

Published: 2018

Journal Articles

Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

Wenyi Shen, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Hideki Makishima, MD PhD, Louis Williams, MD MBA, Sudipto Mukherjee, MD PhD MPH, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2018-99-115228

Published: 2018

Journal Articles

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Bhumika J. Patel, MD, Shimoli Vipul Barot, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hassan Awada, MD, Metis Hasipek, PhD, Swapna Thota, MD, Tomas Radivoyevitch, PhD, Anjali S. Advani, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2018-99-119852

Published: 2018

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Blood (2018) 132 (Supplement 1): 4346.

https://doi.org/10.1182/blood-2018-99-119712

Published: 2018

Journal Articles

Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 4351.

https://doi.org/10.1182/blood-2018-99-119896

Published: 2018

Journal Articles

BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden

Louis Williams, MD MBA, Teodora Kuzmanovic, BA, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Yogenthiran Saunthararajah, MD, Hassan Awada, MD, Vera Adema, PhD, Amy C Graham, BS, MS, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Aziz Nazha, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2018-99-116802

Published: 2018

Journal Articles

Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Teodora Kuzmanovic, Bhumika J. Patel, MD, Yasunobu Nagata, Hassan Awada, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Srinivasa Reddy Sanikommu, MD, Louis Williams, MD MBA, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2018-99-120059

Published: 2018

Journal Articles

Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance

Cassandra M. Hirsch, Michael Clemente, MS, Peter Chomczynski, Bartlomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, PhD, Louis Williams, MD MBA, Valeria Visconte, PhD, Alan Lichtin, MD, Satu Mustjoki, MDPhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 516.

https://doi.org/10.1182/blood-2018-99-116307

Published: 2018

Journal Articles

Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Swapna Thota, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Elizabeth A. Griffiths, MD, Amanda Przespolewski, DO, James E. Thompson, MD, Teodora Kuzmanovic, Aziz Nazha, Shimoli Vipul Barot, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Sudipto Mukherjee, MDPhDMPH, Meghan Scully, NP, Aaron T. Gerds, MDMS, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Manja Meggendorfer, PhD, Eunice S. Wang, MD, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2018-99-119306

Published: 2018

NARROW

MPO as a Novel Susceptibility Gene in Myeloid Malignancies

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia

LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes

Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS

Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes

Distinct Features of Chip-Derived and De Novo MDS

Pathogenic Germline Variants in Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)

BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden

Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance

Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2 mutations after Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only